跳转至内容
Merck
CN
所有图片(1)

文件

安全信息

929352

Sigma-Aldrich

(S,R,S)-AHPC-di-trimethylamide-dioxodisulfide-carbonate ester

登录查看公司和协议定价
所有图片(1)
别名:
S-(1-(((((3R,5S)-1-((S)-2-((tert-butoxycarbonyl)amino)-3,3-dimethylbutanoyl)-5-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-3-yl)oxy)carbonyl)oxy)-2-methylpropan-2-yl) methanesulfonothioate
经验公式（希尔记法）:
C33H48N4O9S3
CAS号:
2417370-08-0
分子量:
740.95
UNSPSC代码:
12352108
NACRES:
NA.21

ligand

VH032

检测方案

≥95%

形式

powder

官能团

disulfide

储存温度

2-8°C

SMILES字符串

CC(C)(C)OC(N[C@@H](C(C)(C)C)C(N1[C@@H](C[C@H](C1)OC(OCC(C)(C)SS(C)(=O)=O)=O)C(NCC2=CC=C(C3=C(C)N=CS3)C=C2)=O)=O)=O

相关类别

应用

Protein degrader building block (S,R,S)-AHPC-di-trimethylamide-dioxodisulfide-carbonate ester enables the synthesis of molecules for degradation of proteins and PROTAC® (proteolysis-targeting chimeras) research. This conjugate contains a von Hippel-Lindau (VHL)-recruiting ligand and a pendant disulfide, linked via a carbonate group. The pendant disulfide allows for targeted degradation of antibodies. Because even slight alterations in ligands and crosslinkers can affect ternary complex formation between the target, E3 ligase, and degrader, many analogs are prepared to screen for optimal target degradation. When used with other protein degrader building blocks, parallel synthesis can be used to more quickly generate degrader libraries that feature variation in crosslinker length, composition, and E3 ligase ligand.

Technology Spotlight: Degrader Building Blocks for Targeted Protein Degradation

Protein Degrader Building Blocks

其他说明

Targeted Protein Degradation by Small Molecules

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

Small-Molecule PROTACS: New Approaches to Protein Degradation

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Impact of linker length on the activity of PROTACs

法律信息

PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license

WGK

WGK 3

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Thomas H Pillow et al.
ChemMedChem, 15(1), 17-25 (2019-11-02)
The ability to selectively degrade proteins with bifunctional small molecules has the potential to fundamentally alter therapy in a variety of diseases. However, the relatively large size of these chimeric molecules often results in challenging physico-chemical properties (e. g., low aqueous
Daniel P Bondeson et al.
Annual review of pharmacology and toxicology, 57, 107-123 (2016-10-13)
Protein homeostasis networks are highly regulated systems responsible for maintaining the health and productivity of cells. Whereas therapeutics have been developed to disrupt protein homeostasis, more recently identified techniques have been used to repurpose homeostatic networks to effect degradation of
Kedra Cyrus et al.
Molecular bioSystems, 7(2), 359-364 (2010-10-06)
Conventional genetic approaches have provided a powerful tool in the study of proteins. However, these techniques often preclude selective manipulation of temporal and spatial protein functions, which is crucial for the investigation of dynamic cellular processes. To overcome these limitations
Momar Toure et al.
Angewandte Chemie (International ed. in English), 55(6), 1966-1973 (2016-01-13)
The current inhibitor-based approach to therapeutics has inherent limitations owing to its occupancy-based model: 1) there is a need to maintain high systemic exposure to ensure sufficient in vivo inhibition, 2) high in vivo concentrations bring potential for off-target side effects, and 3) there is
Philipp M Cromm et al.
Cell chemical biology, 24(9), 1181-1190 (2017-06-27)
Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门